PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 30, 2026Expert Review of Neurotherapeutics0 citations

A critical review of midazolam 10 mg autoinjector for the treatment of convulsive status epilepticus in adults

View Full Paper
FBFrancesco BrigoSLSimona Lattanzi

Key Points

  • To critically assess the midazolam 10 mg autoinjector for convulsive status epilepticus treatment in adults.
  • Review of existing literature regarding midazolam autoinjector efficacy and practicality in emergency care settings.
  • Analysis of adoption factors for autoinjector-based benzodiazepines.
  • Comparison of autoinjector design benefits over traditional therapies.
  • The midazolam autoinjector allows for rapid intramuscular delivery without preparation.
  • Addresses practical limitations faced by existing therapies.
  • Potential to improve early intervention in prehospital settings.

Abstract

The midazolam autoinjector offers a meaningful advance in the treatment of status epilepticus by enabling rapid, consistent intramuscular delivery without preparation. Its design directly addresses the practical limitations of existing therapies and is likely to encourage adoption in prehospital and other time-critical settings. As emergency care increasingly prioritizes early intervention, autoinjector-based benzodiazepines are poised to play an expanding role in modern seizure-rescue strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Brigo et al. (2026) studied this question.

synapsesocial.com/papers/69c9c5a4f8fdd13afe0bd9a2https://doi.org/10.1080/14737175.2026.2652300
Ask AI
Helpful
Bookmark
Share
View Full Paper